Literature DB >> 8516298

Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras.

M R Johnson1, A T Look, J E DeClue, M B Valentine, D R Lowy.   

Abstract

The NF1 gene, which is altered in patients with type 1 neurofibromatosis, encodes neurofibromin, a protein whose GTPase-activating function can negatively regulate GTP-Ras by accelerating its conversion to inactive GDP-Ras. In schwannoma cell lines from patients with neurofibromatosis, loss of neurofibromin was previously shown to be associated with impaired regulation of GTP-Ras. Our analysis of other neural crest-derived tumor cell lines has shown that some melanoma and neuroblastoma cell lines established from tumors occurring in patients without neurofibromatosis contain reduced or undetectable levels of neurofibromin, with concomitant genetic abnormalities of the NF1 locus. In contrast to the schwannoma cell lines, GTP-Ras was appropriately regulated in the melanoma and neuroblastoma lines that were deficient in neurofibromin, even when c-H-ras was overexpressed in the lines. These results demonstrate that some neural crest tumors not associated with neurofibromatosis have acquired somatically inactivated NF1 genes and suggest a tumor-suppressor function for neurofibromin that is independent of Ras GTPase activation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8516298      PMCID: PMC46756          DOI: 10.1073/pnas.90.12.5539

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants.

Authors:  M Trahey; F McCormick
Journal:  Science       Date:  1987-10-23       Impact factor: 47.728

2.  Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms.

Authors:  S A Sørensen; J J Mulvihill; A Nielsen
Journal:  N Engl J Med       Date:  1986-04-17       Impact factor: 91.245

3.  t(11;22) and other chromosomal rearrangements in Ewing's sarcoma.

Authors:  E C Douglass; M Valentine; A A Green; F A Hayes; E I Thompson
Journal:  J Natl Cancer Inst       Date:  1986-12       Impact factor: 13.506

4.  Sarcoma viruses carrying ras oncogenes induce differentiation-associated properties in a neuronal cell line.

Authors:  M Noda; M Ko; A Ogura; D G Liu; T Amano; T Takano; Y Ikawa
Journal:  Nature       Date:  1985 Nov 7-13       Impact factor: 49.962

5.  Cytogenetic features of human neuroblastomas and cell lines.

Authors:  G M Brodeur; A A Green; F A Hayes; K J Williams; D L Williams; A A Tsiatis
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

Review 6.  ras and human tumors.

Authors:  S Rodenhuis
Journal:  Semin Cancer Biol       Date:  1992-08       Impact factor: 15.707

7.  Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung.

Authors:  J Yokota; M Wada; Y Shimosato; M Terada; T Sugimura
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

8.  Microinjection of the ras oncogene protein into PC12 cells induces morphological differentiation.

Authors:  D Bar-Sagi; J R Feramisco
Journal:  Cell       Date:  1985-10       Impact factor: 41.582

9.  A specific chromosomal abnormality in rhabdomyosarcoma.

Authors:  E C Douglass; M Valentine; E Etcubanas; D Parham; B L Webber; P J Houghton; J A Houghton; A A Green
Journal:  Cytogenet Cell Genet       Date:  1987

10.  Synchronous neuroblastoma and von Recklinghausen's disease: a review of the literature.

Authors:  B H Kushner; S I Hajdu; L Helson
Journal:  J Clin Oncol       Date:  1985-01       Impact factor: 44.544

View more
  35 in total

1.  Lack of homozygously inactivated p73 in single-copy MYCN primary neuroblastomas and neuroblastoma cell lines.

Authors:  X T Kong; V A Valentine; S T Rowe; M B Valentine; S T Ragsdale; B G Jones; D A Wilkinson; G M Brodeur; S L Cohn; A T Look
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

2.  The GAP-related domain of neurofibromin attenuates proliferation and downregulates N- and K-Ras activation in Nf1-negative AML cells.

Authors:  Kelly J Morgan; Matthew A Rowley; Stephen M Wiesner; Diane E Hasz; Brian Van Ness; David A Largaespada
Journal:  Leuk Res       Date:  2007-01-12       Impact factor: 3.156

3.  Regulation of expression of two different transcripts of the NF-1 gene in neuroblastoma.

Authors:  R Girgert; P Schweizer
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

4.  Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts.

Authors:  L S Sherman; R Atit; T Rosenbaum; A D Cox; N Ratner
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

5.  Targeted expression of MYCN causes neuroblastoma in transgenic mice.

Authors:  W A Weiss; K Aldape; G Mohapatra; B G Feuerstein; J M Bishop
Journal:  EMBO J       Date:  1997-06-02       Impact factor: 11.598

6.  Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.

Authors:  Robert J Rounbehler; Weimin Li; Mark A Hall; Chunying Yang; Mohammad Fallahi; John L Cleveland
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

7.  NMR-based functional profiling of RASopathies and oncogenic RAS mutations.

Authors:  Matthew J Smith; Benjamin G Neel; Mitsuhiko Ikura
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-04       Impact factor: 11.205

8.  Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

Authors:  Moriah H Nissan; Christine A Pratilas; Alexis M Jones; Ricardo Ramirez; Helen Won; Cailian Liu; Shakuntala Tiwari; Li Kong; Aphrothiti J Hanrahan; Zhan Yao; Taha Merghoub; Antoni Ribas; Paul B Chapman; Rona Yaeger; Barry S Taylor; Nikolaus Schultz; Michael F Berger; Neal Rosen; David B Solit
Journal:  Cancer Res       Date:  2014-02-27       Impact factor: 12.701

9.  Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.

Authors:  Navneet Sangha; Rong Wu; Rork Kuick; Scott Powers; David Mu; Diane Fiander; Kit Yuen; Hidetaka Katabuchi; Hironori Tashiro; Eric R Fearon; Kathleen R Cho
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

Review 10.  Pathways and therapeutic targets in melanoma.

Authors:  Emma Shtivelman; Michael Q A Davies; Patrick Hwu; James Yang; Michal Lotem; Moshe Oren; Keith T Flaherty; David E Fisher
Journal:  Oncotarget       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.